Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 22Active not recruiting 14Withdrawn 7Completed 5Terminated 3Suspended 3Not yet recruiting 3Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 9Specimen Handling 7Educational Status 7Standard of Care 6Interviews as Topic 6Drug Therapy 6Carboplatin 6Blood Specimen Collection 6Radiotherapy 5Nivolumab 5Chemoradiotherapy 5Surgical Procedures, Operative 4Paclitaxel 4Oxaliplatin 4Observation 4Lenalidomide 4Fluorouracil 4Dexamethasone 4pembrolizumab 3lenvatinib 3camrelizumab 3Surveys and Questionnaires 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Gemcitabine 3Fluorodeoxyglucose F18 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × decitabine and cedazuridine drug combination × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡